ABOUT US
OUR PEOPLE
OUR SCIENCE
PIPELINE
PATIENTS & FAMILIES
NEWS
CAREERS
More
EVENTS
PRESS RELEASES
April 1 | 2021
Prilenia to Present at Stifel, BMO, Needham and the European Biotech Investor Days
March 8 | 2021
Prilenia to Present at Upcoming Virtual Healthcare Conferences
January 28 | 2021
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease
January 8 | 2021
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
December 16 | 2020
Additional analyses of Efficacy and Safety of Pridopidine for Huntington’s Disease demonstrate positive effect on functional capacity
October 27 | 2020
Prilenia Enrolls First Patients into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United State
September 17 | 2020
Huntington Study Group Announces A Partnership with Prilenia Therapeutics to Conduct A Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease
September 10 | 2021
Henk Schuring joins Prilenia as Chief Regulatory and Commercialization Officer
June 3 | 2020
Prilenia Therapeutics raises $62.5M to fund late stage trials in HD and ALS
Presentation by Dr. Michael Hayden at the Jefferies Virtual Conference
September 18 | 2019
Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General
